Yingzi Z. Zhen
Beijing Key Laboratory Of Pediatric Hematology Oncology National Key Discipline Of Pediatrics Key Laboratory Of Major Diseases In Children
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost.
Journal: Research and practice in thrombosis and haemostasis
Published: December 20, 2025
Significant PK variability of plasma-derived FIX concentrates in chinese children with Haemophilia B: A fixed single-dose study of factor IX-CTBB.
Journal: Global medical genetics
Published: January 09, 2025
A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.
Journal: Thrombosis research
Published: December 25, 2024
Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.
Journal: Research and practice in thrombosis and haemostasis
Published: July 21, 2024
Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China.
Journal: Clinical therapeutics
Published: June 06, 2024
A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).
Journal: Thrombosis research
Published: April 24, 2024
Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.
Journal: Pediatric investigation
Published: February 13, 2024
The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.
Journal: Hematology (Amsterdam, Netherlands)
Published: February 12, 2024
Real-world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center.
Journal: Pediatric investigation
Published: December 24, 2023
Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China.
Journal: Hematology (Amsterdam, Netherlands)
Published: September 07, 2023
The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China.
Journal: Thrombosis research
Published: January 03, 2023
Last Updated: 09/26/2026